Business Context and Reporting Period
Company: ImmuCell Corporation
Filing Type: Form 10-Q (Unaudited Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 1996
Business Overview: ImmuCell is a biotechnology company focused on developing products to prevent and treat infectious diseases. Key products include First Defense (for calves) and the Kamar Heatmount Detector. The company is also engaged in significant R&D for human health applications, including vaccines for Cryptosporidium and passive antibody treatments for AIDS patients.
Key Financial Metrics
| Metric | Six Months Ended June 30, 1996 |
Six Months Ended June 30, 1995 |
Three Months Ended June 30, 1996 |
|---|---|---|---|
| Total Revenues | $2,270,120 | $2,632,224 | $854,109 |
| Net Loss | $(146,968) | $(10,981) | $(135,290) |
| Net Loss Per Share | $(0.06) | $0.00 | $(0.06) |
| Cash and Equivalents (End of Period) | $1,030,869 | $882,631 | N/A |
| Net Cash Used in Operating Activities | $(274,037) | $102,281 | N/A |
| Total Debt (Current + Long Term) | $695,525 | $777,227 | N/A |
| Working Capital | $1,508,828 | $1,849,580 | N/A |
Note: Gross margin on product sales was maintained between 54% and 56%.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 14% ($362,104) for the six-month period compared to 1995. Product sales dropped 15% ($349,435), primarily due to a general weakness in the beef market, which reduced farmer investment in calf disease prevention products.
- Increased Losses: The net loss for the six months ended June 30, 1996, was $146,968, a significant increase from the $10,981 loss in the same period in 1995. This was driven by R&D expenses exceeding collaborative and grant revenues by $585,000.
- Cash Flow Deterioration: Operating cash flow shifted from positive ($102,281) in 1995 to negative ($274,037) in 1996. Total cash and cash equivalents decreased by $519,142 during the six-month period.
- Debt Reduction: Total debt obligations decreased by approximately $81,700 due to principal payments, though the company continues to service significant long-term debt.
Guidance, Outlook, and Risks
- Strategic Outlook: Management expects to incur further operating losses to aggressively develop new products. The strategy involves demonstrating efficacy in Phase I/II clinical trials to attract corporate partners for funding.
- Liquidity: Management believes current capital resources are sufficient to meet working capital requirements for the next twelve months. However, cash reserves have declined significantly.
- Joint Venture: In July 1996, ImmuCell formed a joint venture with Agri-Mark, Inc. to manufacture lactoferrin. ImmuCell invested $125,000 in fixed assets, while Agri-Mark agreed to invest approximately $650,000. Commercial production is expected to begin in Q1 1997.
- Grant Funding: The company holds two NIAID Phase II SBIR grants totaling approximately $953,000. As of June 30, 1996, approximately $102,000 remained available to fund future expenditures.
- Risks: Key risks include the continued weakness in the beef market affecting core product sales, the high cost of R&D relative to current revenues, and the need for external funding to sustain operations and development.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of operations given the $274,037 negative operating cash flow and $519,142 total cash decrease in six months.
- Joint Venture Terms: Review the specific profit-sharing structure with Agri-Mark (90% to Agri-Mark until capital return) and the timeline for commercial lactoferrin production.
- Grant Expiration: Confirm the status and remaining funding of the NIAID grants, which are critical for offsetting R&D costs.
- Debt Covenants: Assess the impact of current debt levels ($695,525 total) and upcoming principal payments on liquidity.
- Market Dependency: Evaluate the correlation between beef market prices and the sales trajectory of the "First Defense" product line.